All Posts Tagged With: "CBST"
(ALNY) Alnylam States Preclinical Data
Alnylam Pharmaceuticals Inc (ALNY) recently announced pre-clinical data from a trial evaluating its pipeline candidate ALN-HTT for the treatment of Huntington’s disease (HD). ALN-HTT is a novel therapeutic...
(OPTR) Optimer Pharmaceuticals Dificlir Cleared in European Union
Optimer Pharmaceuticals, Inc. (OPTR) and partner Astellas Pharma recently announced that their antibiotic Dificlir received approval in the European Union (EU), not belying expectations. The European Medicines...
(ALNY) Alnylam Pharmaceuticals Analyst Still Bullish
We have maintained an Outperform rating on Alnylam Pharmaceuticals, Inc (ALNY) with a target price of $8.25 per share following appraisal of third quarter 2011 results.
Alnylam Pharmaceuticals Inc....
(ALNY) Alnylam Pharmaceuticals Completes Trial Enrollment
Alnylam Pharmaceuticals Inc. (ALNY) recently announced it has completed enrollment in a mid-stage study of its pipeline candidate ALN-RSV01, an RNA interference technology (RNAi) therapeutic being studied...
(ALNY) Alnylam Pharmaceuticals Reveals ALNTTR01 Trial Data
Alnylam Pharmaceuticals Inc. (ALNY) recently presented data from an early stage study of its pipeline candidate ALN-TTR01 at a scientific conference in Japan. ALN-TTR01 is a systemically delivered RNA interference...
(AAPL) A Busy Week Ahead – Earnings Preview
Earnings Preview 10/14/11
While the earnings season kicked off this past week, only 38 firms reported. The game really gets under way next week, when we will get reports from 336 firms, including 99 members of the S&P 500.
Thus, by the end of the week we...
(ALNY) Alnylam Pharmaceuticals Announces Pipeline Progress
Recently, Alnylam Pharmaceuticals Inc. (ALNY) announced the commencement of an early-stage stage study (n~32) of its RNAi (RNA (Ribo Nucleic Acid) interference) therapeutic program ALN-PCS for treating patients...
(ALNY) Alnylam Pharmaceuticals Analyst Maintains Neutral Rating on Shares
We have maintained a Neutral rating on Alnylam Pharmaceuticals, Inc (ALNY) with a target price of $7.00 per share.
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company developing novel therapeutics...
(MRK) Japanese Approval for Merck Products
Merck (MRK) recently announced that it received approval for three products in Japan. The Japanese Ministry of Health, Labour and Welfare (MHLW) approved Gardasil [human papillomavirus quadrivalent (Types...
(OPTR) Optimer Pharmaceuticals Analyst Maintains Neutral
We have maintained a Neutral rating on Optimer Pharmaceuticals, Inc. (OPTR) with a target price of $12.00 per share.
We find the US Food and Drug Administration’s (FDA) approval of Optimer’s first...
(ALNY) Alnylam Pharmaceuticals Analyst Maintains Neutral on Shares
We have maintained a Neutral rating on Alnylam Pharmaceuticals Inc. (ALNY) with a target price of $9.50 per share.
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company developing novel therapeutics...
(THRX) Theravance Analyst Maintains Neutral on Shares
We have maintained our Neutral recommendation on Theravance, Inc. (THRX) with a target price of $24.00 per share following the announcement of first quarter 2011 financial results.
Theravance’s first...
(THRX) Theravance Analyst Maintains Neutral Rating on Shares
We have maintained our Neutral recommendation on Theravance, Inc. (THRX) with a target price of $24.00 per share following the announcement of first quarter 2011 financial results.
Theravance’s first...
(OPTR) Optimer Pharma Beats on One-Time Gain
Optimer Pharma’s (OPTR) first quarter 2011 earnings of $1.14 per share tellingly reversed the year-ago loss of 39 cents per share and exceeded the Zacks Consensus Estimate of 30 cents. The earnings beat...
(OPTR) Optimer Pharmaceuticals Partners With Cubist Pharmaceuticals for Dificid
Optimer Pharmaceuticals Inc. (OPTR) recently announced an exclusive two-year agreement with Cubist Pharmaceuticals Inc. (CBST) to co-promote...
(ADI) Company News for April 06, 2011 – Corporate Summary
• Expedia, Inc. (NASDAQ:EXPE) and American Airlines (NYSE:AMR) have reached an agreement regarding fees and how travel information should be delivered on its website
• Abercrombie...
(THRX) Theravance Analyst Maintains Neutral on Shares
We are maintaining our Neutral recommendation on Theravance, Inc. (THRX) with a target price of $25.00 after the company’s fourth quarter and fiscal year 2010 financial results.
Theravance’s...
(ALNY) Alnylam Pharmaceuticals Reports Smaller Third Quarter Loss Than Expected
Alnylam Pharmaceuticals Inc.’s (ALNY) third quarter loss of 23 cents per share was narrower than the Zacks Consensus Estimate of 39 cents but wider than the year-ago loss of 22 cents per share. The wider...
(ALNY) Alnylam Pharmaceuticals Analyst Awards Neutral Rating
We are maintaining our Neutral recommendation on Alnylam Pharmaceuticals (ALNY) with a target price of $15.
Alnylam, founded in 2002 and headquartered in Cambridge, Massachusetts,...
(ALNY) Alnylam Pharmaceuticals’ Second Quarter Loss Down on Lower Costs
Alnylam Pharmaceuticals Inc.’s (ALNY) second-quarter net loss of 35 cents per share was 20 cents below the loss per share in the second quarter of 2009. The Zacks Consensus Estimate indicated a loss of...
(CBST) Cubist Pharmaceuticals Earns Some Attention
We were asked last week why we never investigated biotechnology companies. To set the record straight, we own shares in a biotechnology company, Oncothyreon, Inc. (NASDAQ: ONTY),...
(CBST) Cubist Pharmaceuticals Misses Expectations – Revenues Move Up
Cubist Pharmaceuticals (CBST) reported earnings per share of 34 cents for the first quarter of 2010 compared to 13 cents in the year-ago period. Last year’s quarter included a $20 million charge related...
(CBST) Cubist Pharmaceuticals Initiates Mid-stage Trial
Recently, Cubist Pharmaceuticals (CBST) began a mid-stage trial of one of its pipeline candidates, CB-183,315. The drug is being studied to treat patients suffering from diarrhea caused by Clostridium difficile...
(CBST) Cubist Pharmaceuticals Ends Drug Trial
Cubist Pharmaceuticals Inc. (CBST) has stopped a mid-stage trial of one of its pipeline candidates, CB-500,929 (ecallantide). The drug was being studied for lowering blood loss in patients undergoing cardiac...
(CBST) Cubist Pharmaceuticals Misses Estimates
Cubist Pharmaceuticals (CBST) reported earnings per share (EPS) of 38 cents for the fourth quarter of 2009, missing the Zacks Consensus Estimate by 3 cents and down from $1.43 reported in the year-ago period....
(JNJ) Johnson and Johnson Suffers Another Pipeline Setback
Johnson and Johnson (JNJ) has received yet another setback related to its pipeline candidate ceftobiprole, a broad-spectrum antibiotic ? aiming the methicillin-resistant Staphylococcus aureus (MRSA)...
(CBST) Cubist to Aquire Calixa Therapeutics
Recently, Cubist Pharmaceuticals (CBST) decided to acquire a privately held biopharmaceutical company Calixa Therapeutics for an upfront payment of $92.5 million. Additionally, Cubist would be required to...
(CBST) Cubist Pharmaceuticals Beats Earnings Estimates
Cubist Pharmaceuticals, Inc. (CBST) reported a third-quarter net income of 65 cents per share, which was much higher than the Zacks Consensus Estimate of 33 cents. The company’s net income was 48 cents per share in the year-ago quarter. The higher profit...
(THRX) Theravance Earns FDA Approval for Skin Infection Drug
In a quantum achievement, Theravance (THRX) received approval from the US Food and Drug Administration (FDA) to market its Vibativ (telavancin) for complicated skin and skin structure infections (cSSSI) caused by Gram-positive bacteria.
Vibativ,...
(JNJ) Johnson & Johnson Responds to FDA Questions on Antibiotic Drug Trials
We are pleased to hear that the US Food and Drug Administration (FDA) has accepted Johnson & Johnson’s (JNJ) response on clinical trial-related issues. Last month, the agency had warned the company for not maintaining proper records during the trial...